Русский
English
عربي
Hikma Pharmaceuticals
History and Development:
- The company was founded by Samih Darwazah in 1978 in Amman, Jordan.
- In August 1996, it became the first Arab company to export pharmaceutical products to the United States.
- In 2005, Hikma listed its shares on the London Stock Exchange and became a part of the FTSE 100 index.
- Since then, the company has expanded its presence by acquiring pharmaceutical companies in various countries, including Egypt, Germany, and Saudi Arabia.
Product Portfolio:
Hikma Pharmaceuticals develops, manufactures, and distributes a wide range of medicines, including:
- Injectable Drugs: Such as Argatroban, Fentanyl, Phenylephrine, Robaxin, and Iron Gluconate.
- Branded Medicines: Including Amoclan, Blopress, Omnicef, Prograf, and Suprax.
- Generic Medicines: Including Amoxicillin, Cephalexin, Doxycycline, Methocarbamol, and Prednisolone.
Global Presence:
Hikma operates 29 facilities across 11 countries: the USA, Portugal, Italy, Jordan, Saudi Arabia, Algeria, Germany, Egypt, Morocco, Tunisia, and Sudan.
Brand products
OUR PARTNERS
